Joseph G. Jurcic
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2025
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2025
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2025
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2024
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2024
Purpose: The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab. Patients and Methods: Eighteen patients (median age, 64 years; range, 45–80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg. Results: The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. Myelosuppression was the most common toxicity. Significant extramedullary toxicities were limited to transient grade 3 liver function abnormalities. Pharmacokinetics were determined by gamma counting serial whole blood, plasma, and urine samples at energy windows for the 225Ac daughters, francium-221 and bismuth-213. Two-phase elimination kinetics were seen with mean plasma t1/2 − α and t1/2 − β of 1.9 and 38 hours, respectively. Peripheral blood blasts were eliminated in 10 of 16 evaluable patients (63%) but only at doses of ≥ 37 kBq/kg. Bone marrow blasts were reduced in 10 of 15 evaluable patients (67%), including 3 patients with marrow blasts ≤ 5% and one patient with a morphologic leukemia-free state. Conclusions: Therapy for AML with the targeted α-particle generator 225Ac-lintuzumab was feasible with an acceptable safety profile. Elimination of circulating blasts or reductions in marrow blasts were observed across all dose levels.
Year:
2022
Collaborators (23)
Prabhjot Mundi
Assistant Professor
Columbia University Irving Medical Center
Peter Sims
Assistant Professor
Columbia University Irving Medical Center
Hanina Hibshoosh
Professor of pathology at CUIMC
Columbia University
Guy M. McKhann
Florence Irving Associate Professor of Neurological Surgery
Columbia University Irving Medical Center
Ana Tergas
Rutgers, The State Univ. of NJ
Kenneth Olive
Assistant Dean of Graduate Curricula and Associate Professor of Medicine
Columbia University Irving Medical Center
Guarionex Joel DeCastro
Associate Professor
Columbia University
Jason D. Wright
-
Andrew Kung
Chair
Memorial Sloan Kettering Cancer Center
Mariano Alvarez
Chief Scientific Officer
KweHealth, LLC
Gary K. Schwartz
Case Western Reserve University
Andrew Lassman
Chief, Neuro-Oncology Division
Columbia University Irving Medical Center
Dawn L. Hershman
Columbia University Irving Medical Center
Kevin Kalinsky
Emory University
Katherine Crew
Professor
Columbia University Irving Medical Center
Alfred I. Neugut
-
Daniel Diolaiti
Fred Hutchinson Cancer Research Center
Michael Kluger
Professor of Surgery
NYU Langone Health
Andrea Califano
Columbia University Irving Medical Center
Eugene Douglass
Assistant Professor
University of Georgia
Catherine Shu
Columbia University Irving Medical Center
Melissa K. Accordino
Columbia University
Jeffrey Bruce
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.